Lead magnets for Series A companies: the 90-day install for healthcare and life sciences in the APAC region
The exact 90-day plan for standing up lead magnets at Series A — the point where the founder can no longer be every function. Written for commercial leaders at healthtech, medtech, and life-sciences companies in the APAC region.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the APAC region. In this market, APAC buyers span very different cultures and reward vendors who adapt playbooks per market, so the way you install lead magnets has to be shaped to that reality from day one.
Series A is the moment lead magnets stops being optional. The founder has to step out of some of the work, the plan requires a defensible growth number, and every quarter compounds toward the next raise.
Day 1 to 30: diagnosis and instrumentation. Name the constraint, write the ICP, wire MQL-to-opportunity conversion by source into the board pack.
Day 31 to 60: first live cycle at 20% of planned volume. Founder still in every review. Kill criteria written and enforced.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the APAC region it is compounded by the fact that market-by-market adaptation, not one-size playbooks is what actually gates growth. Lead magnets is only useful here when it is pointed at both constraints at once.
Day 61 to 90: ramp to full volume, hire the first dedicated operator, and hand off ops. Founder retains strategy and the weekly review.
By day 90 the metric is legible and the trajectory is defensible. This is what turns a Series A story into a Series B round.
Trap most Series A companies fall into: gating anything a Google search could replace. It usually shows up around day 45 when the founder tries to hire ahead of the model.
The Series A version of lead magnets looks small compared to what you will build at Series B. That is the point — it is a foundation, not a monument.
Concretely for healthcare and life sciences in the APAC region: the healthcare teams that install this get past procurement instead of dying in it, and the APAC teams that install this stop treating the region as one market and start winning it as many. That is the reason it is worth installing lead magnets deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Lead Generation · healthcare · APAC — answered
- Does lead magnets work for healthcare and life sciences in the APAC region?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in the APAC region, APAC buyers span very different cultures and reward vendors who adapt playbooks per market. The healthcare teams that install this get past procurement instead of dying in it.
- Should we start lead magnets before Series A?
- Yes if the founder has time; the Series A version is the same model at higher spend.
- How much of the round should fund lead magnets?
- Meaningful — often 20–30% of the growth line — but only after diagnosis.
- When do we hire the first lead magnets operator?
- Around day 60, once the model has run one full cycle with the founder.
- What Series A trap should we avoid?
- Gating anything a Google search could replace — usually a premature senior hire.
- What is the APAC-specific pitfall when running lead magnets for healthcare?
- Importing a playbook that was built for another market. In the APAC region, APAC buyers span very different cultures and reward vendors who adapt playbooks per market — the install has to reflect that.
Growth Broker editorial
Filed under lead generation · healthcare · apac